Monkeys that were vaccinated against the Ebola virus developed «long-term» immunity to the pathogen, scientists say.
In experiments carried out by the National Institutes of Health (NIH) of the United States, it was found that immunity in primates appeared at least 10 months.
Clinical trials of the vaccine with humans began in the United States this week and will be extended to the United Kingdom and Africa.
The vaccine, which is one of several experimental treatments being tested to help contain the virus in Africa, was developed by the NIH’s National Institute of Allergy and Infectious Diseases and the pharmaceutical company GlaxoSmithKline.